Hong Kong Zhongda discovers new pathogenesis of liver cancer

The Chinese University of Hong Kong announced on the 23rd that the school’s research team has found that high squalene epoxidase (SQLE) induces non-alcoholic fatty liver and its associated liver cancer; and that terbinafine can effectively curb non-alcoholic fatty liver-induced Hepatoma cells grow.

According to the Hong Kong University of Technology, non-alcoholic fatty liver disease is an important cause of liver cancer, but the medical community is not aware of the mechanism, and there is no effective treatment and prevention drugs. At present, about 30% of adults in Hong Kong suffer from nonalcoholic fatty liver disease.

The Hong Kong University of Science and Technology research team conducted a genetic sequencing of 18 cases of non-alcoholic fatty liver-induced liver cancer and normal liver tissue. It was found that SQLE was significantly higher in such liver cancer patients; and the survival time of high-SQLE liver cancer patients was shortened.

SQLE is a key enzyme in cholesterol synthesis in humans. The team used genetic engineering to construct an experimental mouse model with high-hepatic HEE cells. The results showed that there was a significant increase in the incidence of hepatocellular carcinoma in the experimental mice that had the genetic alteration of SQLE, thus demonstrating that SQLE is a carcinogenic factor for non-alcoholic fatty liver-induced liver cancer.

The researchers also found that anti-fungal drugs that inhibit SQLE, called terbinafine, can be used to treat and prevent non-alcoholic fatty liver-induced liver cancer, providing a new direction for the treatment of such liver cancer.

Professor Yu Jun, professor of internal medicine and pharmacotherapeutics at the Hong Kong University of Chinese Medicine, who led the study, said that SQLE plays a key role in non-alcoholic fatty liver-induced liver cancer. They will continue to study terbinafine treatment and prevention of such liver cancer. It is hoped that the results of this study can be transformed into clinical applications in the future.

The research was published on April 18 in the internationally renowned medical journal "Scientific Translational Medicine." (According to Xinhua News Agency)

Lower Blood Pressure Plant Extract

Lower Blood Pressure Plant Extract,Nattokinase Powder,Nattokinase Extract,Nattokinase Extract For Cardiovascular

Fufeng Sinuote Biotechnology Co.,Ltd. , https://www.sntbiology.com